First human efficacy study of a plant-derived influenza vaccine
Open Access
- 13 October 2020
- journal article
- editorial
- Published by Elsevier BV in The Lancet
- Vol. 396 (10261), 1464-1465
- https://doi.org/10.1016/s0140-6736(20)32010-9
Abstract
No abstract availableThis publication has 6 references indexed in Scilit:
- Efficacy, immunogenicity, and safety of a plant-derived, quadrivalent, virus-like particle influenza vaccine in adults (18–64 years) and older adults (≥65 years): two multicentre, randomised phase 3 trialsThe Lancet, 2020
- End of season influenza vaccine effectiveness in adults and children in the United Kingdom in 2017/18Eurosurveillance, 2019
- Relative Effectiveness of Cell-Cultured and Egg-Based Influenza Vaccines Among Elderly Persons in the United States, 2017–2018The Journal of Infectious Diseases, 2018
- Cell culture-derived influenza vaccines in the severe 2017–2018 epidemic season: a step towards improved influenza vaccine effectivenessnpj Vaccines, 2018
- Efficacy of Recombinant Influenza Vaccine in Adults 50 Years of Age or OlderThe New England Journal of Medicine, 2017
- Expression of hepatitis B surface antigen in transgenic plants.Proceedings of the National Academy of Sciences of the United States of America, 1992